Hyperphosphatemia remains a major challenge in managing patients with kidney failure and is associated with significant morbidity and mortality.  In a Mini-Review recently published in AJKD, authors Ian Da Silva Lugo and Jaime Uribarri discuss how traditional approaches such as dietary phosphate restriction, oral phosphate binders, and dialysis modifications, often provide insufficient control of serum phosphate levels.

Comparative Features of Current Therapies to Correct Hyperphosphatemia in Patients with Kidney Failure. Table 1 from Da Silva Lugo et al, © National Kidney Foundation.

AJKDBlog’s Interviews Editor, Timothy Yau (@Maximal_Change) sat down with Drs. Roger Rodby (@NephRodby) and William Whittier (@TWhittier_RUSH) to review the available information about the clinical use of tenapanor, including its safety profile, and provide some clinical suggestions for its practical use.

If the embedded player above doesn’t work, please click here to watch the video interview. If you are interested in the Sherman Perspective that is referenced in this interview, click here. Special thanks to Drs. Rodby and Whittier for their time and insight!

To view this Mini-Review by Da Silva Lugo and Uribarri [FREE], please visit AJKD.org:

Title: Tenapanor: An Update on Evidence of Effectiveness and Guidance on Practical Use
Authors: Ian Da Silva Lugo and Jaime Uribarri
DOI: 10.1053/j.ajkd.2025.06.008